MONDAY, Feb. 27 (HealthDay News) -- "Chemo brain," the honor given to the mental fog and related memory problems that can occur for the time of and after chemotherapy, may last for two decades after breast cancer management, new research suggests.

In the of recent origin study, 196 women with breast cancer who were treated by chemotherapy roughly 21 years earlier performed worse in c~tinuance tests of their memory, processing make haste and other thinking ("cognitive") skills whereas compared to their counterparts who had at no time been diagnosed with cancer.

Participants had whole been treated for breast cancer with a chemotherapy combination that included the drugs cyclophosphamide, methotrexate and 5-fluorouracil between 1976 and 1995. This regimen was considered the type of care for breast cancer worldwide from the 1970s to the 1990s and was received by thousands of women during this time. Women in the study were having lived 50 to 80.

"To our cognition, this is the first study to suggest that subtle cognitive deficits may have ~ing among the long-term effects of chemotherapy, especially of the earlier regimens," study former Sanne Schagen, a group leader at the division of psychosocial research and epidemiology at the Netherlands Cancer Institute/Antoni covered wagon Leeuwenhoek Hospital in Amsterdam, said in a recent accounts release from the American Society of Clinical Oncology.

She added that under which circumstances the results don't suggest that conscience cancer survivors need to be watched more closely for memory and thinking problems, they could govern referrals to support services as needed.

In not partial, women who received this chemotherapy preservation of health had lower scores on tests of their ingenuity to recall words, information-processing make haste, and coordination of thinking and pointer movement, such as putting pegs in a provision, than women who did not. The results adhering these tests were similar to those seen mixed people who had just completed chemotherapy, and their bulk was comparable to roughly six years of mature years-related decline in mental function, the study authors famed.

The researchers also assessed the women notwithstanding depression and self-reported memory problems being of the cl~s who part of the study. The women who had accepted chemotherapy also had more memory complaints than their peers who did not bear chemo, but these complaints were not cognate to how they performed on memory tests.

The study findings were published online Feb. 27 in the Journal of Clinical Oncology.

Dr. Tim Ahles, the monitor of the Neurocognitive Research Laboratory at Memorial Sloan-Kettering Cancer Center in New York City, declared this new study is the in the ~ place to illustrate that long-term breast cancer survivors are placid experiencing difficulty with their thought processes. "It adds to the notion that these effects may be protracted term and permanent," he said.

The personal estate of so-called chemo brain transform from person to person, and not total people who receive chemotherapy will expand or be affected by these issues.

"If someone is a professional who has one extremely demanding job, even a illiberal change may be problematic, whereas in spite of someone who is retired and has a besides relaxed lifestyle, it may be not so much of a problem," Ahles said. "For women who are newly diagnosed and looking at treatments, it is after that important to know that not everyone experiences these deficits."

In terms of prevention and treatment, there are greater amount of questions than answers right now. "This is one active area of research, and at that time that we have identified this is a certain problem, people are turning their attention to what we can do to give a lift treat and reduce some of the negative impulse," Ahles noted.

Dr. Marisa Weiss, president and fail of Breastcancer.org and director of thorax radiation oncology and breast health outreach at Lankenau Medical Center in Wynnewood, Pa., before-mentioned the new study "shows only a scarcely any pieces of this complex puzzle."

She said it wasn't clear whether artful losses in mental function were right to cancer alone, the effects of other therapies so as anti-estrogen treatments, or other factors.

Although the study uncovered one association between the cancer treatment and remembrance problems in the study patients, it did not substantiate a cause-and-effect relationship.

"There were divers differences between these two groups," Weiss uttered, including whether or not they underwent the precise chemotherapy regimen. "We still need to ~ up in the other puzzle pieces face to face with we can see what the represent is going to look like."

Dr. Stefan Gluck, a professor in the sphere of duty of medicine and assistant director of the University of Miami/Sylvester Comprehensive Cancer Center, said that the new findings confirm this is not a of short duration problem. "It may be the connection of drugs used 20 years past were more likely to cause these issues," he afore~. "Today's drugs may be smaller likely to cause long-term cognitive movables."

He also added that drugs taken ~ dint of. many breast cancer survivors to stave off a breast cancer recurrence ~wards treatment may also contribute to chemo brain.

More advice

Learn more about coping with chemotherapy lateral effects from the U.S. National Cancer Institute.

@yahoonews ~ward Twitter, become a fan on Facebook